Market capitalization | $142.50m |
Enterprise Value | $77.69m |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | negative |
EV/Sales (TTM) EV/Sales | 131.68 |
P/S ratio (TTM) P/S ratio | 241.53 |
P/B ratio (TTM) P/B ratio | 1.75 |
Revenue growth (TTM) Revenue growth | -94.34% |
Revenue (TTM) Revenue | $590.00k |
As a Free StocksGuide user, you can view scores for all 6,914 stocks worldwide.
6 Analysts have issued a aTyr Pharma, Inc. forecast:
6 Analysts have issued a aTyr Pharma, Inc. forecast:
Jun '24 |
+/-
%
|
||
Revenue | 0.59 0.59 |
94%
94%
|
|
Gross Profit | -1.97 -1.97 |
125%
125%
|
|
EBITDA | -60 -60 |
32%
32%
|
EBIT (Operating Income) EBIT | -63 -63 |
31%
31%
|
Net Profit | -58 -58 |
29%
29%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
aTyr Pharma, Inc. develops protein therapeutics and novel class of biologic drugs. It plans to build a pipeline of therapeutic products based on Physiocrine biology. The company has established a dominant intellectual property estate to protect the core therapeutics as well as associated diagnostics. It operates in a single accounting segment. aTyr Pharma was founded by Paul Schimmel, Xiang-Lei Yang and Bruce Beutler on September 8, 2005 and is headquartered in San Diego, CA.
Head office | United States |
CEO | Sanjay Shukla |
Employees | 59 |
Founded | 2005 |
Website | www.atyrpharma.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.